Magnetic Resonance Spectroscopy Applications in Breast Cancer Metabolism

Magnetic resonance spectroscopy (MRS) offers a non-invasive window into the altered biochemical pathways that underpin breast cancer initiation, progression and response to therapy. By detecting and quantifying metabolites such as choline-containing compounds, phosphomonoesters, phosphodiesters and lipid moieties, in vivo MRS captures the hallmarks of oncogenic transformation—enhanced membrane synthesis, upregulated glycolysis and dysregulated phospholipid turnover. High-field proton (1H) MRS distinguishes malignant lesions from benign tissue through elevated total choline signals, while phosphorus (31P) MRS resolves the dynamics of phosphoethanolamine and phosphocholine pools, providing early indicators of treatment efficacy. Advances in hyperpolarised 13C MRS enable real-time monitoring of metabolic flux through glycolytic and tricarboxylic acid pathways, revealing tumour heterogeneity and microenvironmental influences. Integration with anatomical and functional MRI yields a multiparametric framework that quantifies structural, perfusion and metabolic parameters in a single examination. Ex vivo high-resolution NMR of biopsy samples and biofluids further refines metabolite signatures, informing personalised therapeutic strategies. Taken together, the spectrum of MRS methodologies illuminates key metabolic vulnerabilities in breast tumours, supports prognostic stratification and underpins the development of metabolism-targeted interventions.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Magnetic Resonance Spectroscopy Applications in Breast Cancer Metabolism publication trend

The graph below shows the total number of articles in magnetic resonance spectroscopy applications in breast cancer metabolism across all publications each year (not limited to Nature Index journals).

Technical terms

Magnetic resonance spectroscopy (MRS): A non-invasive imaging technique that measures the chemical composition of tissue by detecting specific nuclei such as 1H, 13C or 31P.

Total choline (tCho): The sum of choline-related metabolites (phosphocholine, glycerophosphocholine and free choline) indicative of cell membrane turnover.

Phosphomonoesters (PME) and phosphodiesters (PDE): Metabolite pools measured by 31P MRS, representing precursors and breakdown products of membrane phospholipids respectively.

Hyperpolarisation: A method to enhance the magnetic resonance signal of low-sensitivity nuclei (e.g. 13C) by temporarily increasing spin alignment, enabling real-time metabolic flux measurements.

Neoadjuvant chemotherapy (NAC): Systemic treatment administered before surgical resection to shrink tumours, where metabolic changes detected by MRS can predict pathological response.

References

1. Breast Tissue Metabolism by Magnetic Resonance Spectroscopy. Metabolites (2017).
2. Magnetic Resonance Imaging (MRI) and MR Spectroscopic Methods in Understanding Breast Cancer Biology and Metabolism. Metabolites (2022).
3. In vivo proton magnetic resonance spectroscopy of breast cancer: a review of the literature. Breast Cancer Research (2012).
4. Early detection of changes in phospholipid metabolism during neoadjuvant chemotherapy in breast cancer patients using phosphorus magnetic resonance spectroscopy at 7T. NMR in Biomedicine (2019).
5. Intra-tumoural lipid composition and lymphovascular invasion in breast cancer via non-invasive magnetic resonance spectroscopy. European Radiology (2020).
6. Can Multi-Parametric MR Based Approach Improve the Predictive Value of Pathological and Clinical Therapeutic Response in Breast Cancer Patients?. Frontiers in Oncology (2018).